Jinsun Kim is a Vice President and leader of Bioprocess Development Group of IMNEWRUN. He has over 20 years of deep experience in the process development of biosimilars and innovative biologics, including recombinant proteins and monoclonal antibodies. Since joining the company in 2021, he has overseen the CMC strategy and execution for discovery and preclinical programs. Prior to his role at IMNEWRUN, Mr. Kim spent 9-years at Samsung Bioepis, where he led the development of cell lines and cultivation processes for multiple successful biosimilar products. As the Director of the cell culture group, he led the development of biosimilar products and technology transfers to Contract Manufacturing Organizations (CMOs) and conducting process characterizations through scale-down modeling. Furthermore, he contributed to the development of platform technologies for delivering drugs subcutaneously, leading the development of microbial-derived hyaluronidase. Before joining Samsung Bioepis, Mr. Kim worked at Hanmi Pharmaceutical for 10 years, where he participated in the development of long-acting proteins technology, LAPSCOVERY, as a researcher and project leader. He played a crucial role in developing the Fc carrier protein, essential for LAPSCOVERY, and contributed to the advancement of the LAPSCOVERY pipelines, including hGH, GCSF, IFN-a, and various other bioactive proteins. Mr. Kim earned his Bachelor's and Master's degrees in biotechnology and bioscience from Hankuk University of Foreign Studies.